Sign in
Taking people in United StatesPhase 2/3

A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
150 people, planned
Started
4 Jun 2026
Expected to end
Jul 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Non-invasive vagus nerve stimulator plus nicotine replacement patches
  • nicotine replacement patches
Record updated
25 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • 18 years of age or older at the time of consent
  • Currently smoking cigarettes on a regular basis
  • Motivated to stop smoking (on a scale of 0 to 10, motivation must be 3 or above)
  • Ability to participate fully in all aspects of the study
  • Have the ability to provide informed consent
  • Have no contraindicating comorbid health conditions that would interfere with study participation, as determined by the clinical investigators

Who cannot take part

  • Patients who are or have used an investigational drug within the past 30 days
  • Patients who are currently using medication(s) known to interact with varenicline
  • Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Patients who have clinically significant acute/chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, psychological, respiratory, or metabolic disease
  • Patients with a known allergy to nicotine patches or varenicline
  • Patients with a personal history of acute pancreatitis, hypoglycemia, acute kidney injury or impairment of renal function, type 1 diabetes or diabetic ketoacidosis, and/or severe gastrointestinal disease such as gastroparesis
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
  • Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded; Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine devices, surgical sterilization, and abstinence. The study does not include vulnerable populations; Specifically, the study does not include fetuses, neonates, pregnant women, children (<18 years of age), prisoners, institutionalized individuals, or other vulnerable populations; All female participants of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during study participation
  • Patients with a current moderate/severe depression as assessed by a score of ≥10 on the Patient Health Questionnaire-9 (PHQ-9)
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have a metallic device such as a stent, bone plate, or bone screw implanted at or near your neck
  • Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesContact: Shawn Fokken, CCRPTaking people

About the trial

What the trial wants to find out

The purpose of this study is to provide preliminary evidence for the efficacy of 12 weeks of vagal nerve stimulation (VNS) and nicotine replacement therapy (NRT) for increasing smoking abstinence rates.

The 2 groups in the trial

  • Vagal Nerve Stimulator and Nicotine Replacement PatchesTreatment being tested

    This arm will receive nicotine patches (21 mg) for 12 weeks and brief behavioral therapy (through the self-help manual Smoke Free and Living It), as well as the vagal nerve stimulator (VNS) device to use during these 12 weeks while trying to stop smoking. The VNS delivers up to 30 stimulations over 24 hours.

    Treatment: Non-invasive vagus nerve stimulator plus nicotine replacement patches

  • Nicotine Replacement PatchesExisting treatment, for comparison

    This arm will receive nicotine patches (21 mg) for 12 weeks and brief behavioral therapy (through the self-help manual Smoke Free and Living It).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation
Record updated
25 September 2026